ABHI (Association of British Healthcare Industries) considers focus on neuroscience sector:
This article was originally published in Clinica
The Association of British Healthcare Industries (ABHI) is considering setting up a special interest section focusing on neuroscience issues. The ABHI has called on its members for expressions of interest, but this is also an opportunity for non-members to become involved in the UK's leading medical technology industry association. According to the ABHI, the new sub-group's leading roles would be to: represent the interests of the neurosciences sector of the ABHI; encourage smaller companies in this area to participate in ABHI activities; and provide a link between the sector and professional bodies. The ABHI contact is Judith Mellis (Judith.Mellis@abhi.org.uk).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.